FDA Approves New indication for Briviact (brivaracetam) as Monotherapy Treatment of Partial-Onset Seizures in Adults

Atlanta, Georgia (U.S.)& Brussels (Belgium), 15 September, 2017 – 0700 (CEST): UCB announced today that the U.S. Food and Drug Administration (FDA) has approved a supplemental new drug application (sNDA) for Briviact (brivaracetam) CV as...
Source: Drugs.com - New Drug Approvals - Category: Drugs & Pharmacology Source Type: news